Q3 Financial Summary for Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Overview of Business Results

During the cumulative consolidated period of Q3 for the fiscal year ending March 2026, revenue increased to JPY 36,488 million (YoY +23.2%), operating income rose to JPY 7,767 million (YoY +37.1%), and EBITDA grew to JPY 9,682 million (YoY +27.1%). By segment, the Health Big Data business showed steady performance with revenue of JPY 31,629 million (YoY +26.4%) and segment profit of JPY 8,579 million (YoY +32.1%), while the Telemedicine business also expanded with revenue of JPY 4,858 million (YoY +5.0%) and segment profit of JPY 1,836 million (YoY +5.8%). Following the stock transfer of Noa Medical System Inc., the Pharmacy Support Business has been classified as a discontinued operation, and comparisons with the previous period are based on continuing operations only.

Financial Position and Cash Flow

Total assets increased by JPY 13,163 million from the end of the previous consolidated fiscal year to JPY 156,184 million. Total liabilities rose by JPY 9,218 million to JPY 73,763 million, while total equity increased by JPY 3,945 million to JPY 82,421 million. Cash flow from operating activities resulted in an inflow of JPY 5,598 million, cash flow from investing activities was an outflow of JPY 7,742 million, and cash flow from financing activities recorded an inflow of JPY 206 million, leading to cash and cash equivalents of JPY 30,239 million—down JPY 1,936 million from the end of the previous period. There is no change to the earnings guidance for the full fiscal year ending March 2026.